|Day Low/High||44.06 / 44.69|
|52 Wk Low/High||33.55 / 49.41|
Despite disappointing performance this year, the strategy has shown solid return in the past.
It was not a great year for this value portfolio, with only 5 stocks in positive territory for the year.
This mix of 20 deep-value names was outperforming a couple Russell indices three months back but is trailing them now.
This portfolio of 10 eclectic names has pushed higher since the start of 2018 and is up 40.5% since inception just 14 months ago.
Fossil Group has done most of the heavy lifting among the small stocks in the portfolio, though there are other winners, too.
FOSL is up 92% since I launched this group, while HIBB is ahead 27%.
It is always important see how such value screens perform in times of market stress.
The Double-Net Dividend portfolio has been a success so far and it's largely due to a beaten-down sector.
One month in, 15 out of 20 names are in positive territory, with Fossil Group soaring 39%.
Overall it was a good year for this somewhat off the wall screen that I developed several years ago as a way to find seemingly cheap companies.
Electro Scientific Industries leads a parade of value stocks that have performed quite nicely in a growth-oriented market.
Despite the disparity this year between growth and value, my 2017 Double Net Value Portfolio is not struggling.
Double-Net Dividend stocks, which some would call misfits, doing OK so far.
Buying's good for the acquirers, which should give other companies ideas.
Just two months after its creation, the portfolio handily is beating the Russell 2000 Index and Russell Microcap Index.
'Double-nets' have been fertile ground for acquisitions.
The list is dominated by retailers, of which there are four; that's unfortunate, given the pressure that sector is facing these days.
An eclectic mix of 20 companies made my cut of stocks trading at 1x to 2x net current asset value.
The electronic components name that recently bought Premier Farnell is undergoing a noteworthy transition.
Checking the gauges for underperformance, none of them look good.
This is what matters in making more money for your portfolio.
Jim Cramer, The Street's Action Alerts PLUS Portfolio Manager and host of CNBC's 'Mad Money,' said Allergan (AGN) is a stock to hold onto.